Summary
The pharmacokinetics and endocrine effects of the LHRH analogue buserelin [D-Ser(TBU)6-LHRH], released from biodegradable implants, were studied in 14 patients with stage C and D prostate cancer. Six patients received a subcutaneous implant of 3.3 mg buserelin monthly, and 8 patients received a subcutaneous implant of 6.6 mg buserelin every two months. Serum levels of buserelin decreased rapidly immediately after implantation. After 1–2 weeks a more gradual decline occurred, while in the two-monthly treated group a third phase of the elimination curve started after 5 weeks. Mean serum buserelin levels just before the next implantation in the two groups were not different. Urinary excretion of buserelin followed the same pattern. Serum LH levels in both groups became non-detectable 2 weeks after the first implant. This decrease of LH levels was accompanied by a suppression of serum testosterone to concentrations below 1 nmol/l (castration level). Side effects were not different from those observed with the intranasal application of buserelin. It is concluded that the subcutaneous application of buserelin is an easily administered form of treatment which has more profound and more reliable endocrine effects when compared with the intranasal administration of the drug. The greatest advantage of the new preparation is that the intervals between applications may be prolonged to at least 2 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borgmann V, Hardt W, Schmid-Gollwitzer M, Adenauer H, Nagel R (1982) Sustained suppression of testosterone production by the luteinising-hormone-releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet I:1097–1099
Debruyne FMJ, Karthaus HFM, Schröder FH, de Voogt HJ, de Jong FH, Klijn JGM (1985) Results of a Dutch phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer. In: Schroeber FH, Richards B (eds) Therapeutic principles in metastatic prostatic cancer. Liss, New York, pp 251–270
Furr BJA, Hutchinson FG (1985) Biodegradable sustained release formulation of the LH-RH analogue “Zoladex” for the treatment of hormone-responsive tumours. In: Schroeder FH, Richards B (eds) Therapeutic principles in metastatic prostatic cancer. Liss, New York, pp 143–153
Grant JBF, Ahmed SR, Shalet SM, Costello CB, Howell A, Blacklock NJ (1986) Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. Br J Urol 58:539–544
Jacobi GH, Wenderoth UK, van Wallenberg H, Gatto M, Hohenfellner R (1988) LH-RH analogues for pallition of advanced prostatic carcinoma. A critical review after five years of experience. In: Höffken K (ed) LH-RH agonists in oncology. Springer, Berlin Heidelberg New York, pp 72–84
Kuhl H, Kaplan H-G, Taubert H-D (1976) Die Wirkung eines neues Analogs des LH-RH, D-Ser (TBU)6-EA10-LH-RH, auf die Gonadotropin-Freisetzung bei Männern. Dtsch Med Wochenschr 101:361–364
Sandow J, Beier B (1985) LHRH agonist — mechanism of action and effect on target tissues. In: Schroeder FH, Richards B (eds) Therapeutic principles in metastatic prostatic cancer. Liss, New York, pp 121–142
Sandow J, Fraser HM, Seidel H, Krauss B, Jerabek-Sandow G, von Rechenberg W (1987) Buserelin: pharmacokinetics, metabolism and mode of action. Br J Clin Pract [Suppl 48] 41:6–14
Schroeder FH, Lock MTWT, Chadha DR, Debruyne FMJ, Karthaus HFM, de Jong FH, Klijn JG, Matroos AW and de Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus Cyproteronacetate. J Urol 137:912–919
Smith JA Jr (1987) New methods of endocrine management of prostatic cancer. J Urol 137:1–10
Smith JA Jr (1985) Treatment of metastatic carcinoma of the prostate with Leuprolide, an LHRH analogue. In: Schroeder FH, Richards B (eds) Therapeutic principles in metastatic, prostatic cancer. Liss, New York, pp 279–285
Van Cangh PJ and Opsoner RJ (1987) Treatment of advanced carcinoma of postate with depot luteinizing hormone-releasing hormone analogue (ICI-118630). J Urol 137:61–64
Verjans HL, Cooke BA, De Jong FH, De Jong CMM, Van der Molen HH (1973) Evaluation of radioimmunoassay for testosterone estimation. J Steroid Biochem 4:665–668
Waxman JH, Sandow J, Man A, Barnett MJ, Magill PJ (1986) The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemoth Pharmacol 18:174–175
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blom, J.H.M., Hirdes, W.H., Schröder, F.H. et al. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol. Res. 17, 43–46 (1989). https://doi.org/10.1007/BF00261050
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00261050